Biontech Se ADR (BNTX)

$105.87 +0.11 (0.10%)
Market Cap 23.82B
Revenue (ttm) 2.98B
Net Income (ttm) -719.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.18%
Debt to Equity Ratio 0.01
Volume 631,900
Avg Vol 1,128,460
Day's Range N/A - N/A
Shares Out 225.18M
Stochastic %K 6%
Beta 1.49
Analysts Strong Sell
Price Target $141.25

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
WatchTheseTickers
WatchTheseTickers Feb. 13 at 9:31 PM
OLB sitting in that reversal pocket exhaustion, zero borrow supply, undervalued zone near .30 and can see $1.00+. Low float runners often ignite from setups exactly like this. Do your DD. $MRNA $BNTX $NVAX $PFE $LLY
0 · Reply
QHD
QHD Feb. 13 at 8:35 PM
$AUTL Key Points of this Agreement: Strategic alliance leverages manufacturing/commercial infrastructure as well as technology w/ aim to advance both companies’ auto CAR-T programs to market * $BNTX secures right to use AUTL’s manufacturing capacity in a cost-efficient set-up to accelerate development of BNT211 into pivotal trials in CLDN6+ tumors * BNTX to support launch & expansion of development program of AUTL’s lead cell therapy candidate obe-cel & will receive a royalty on net sales * BNTX has co-commercialization options for AUTO1/22 & AUTO6NG programs * BNTX has option to access suite of AUTL target binders & cell programming technologies to support BNTX’s development of in vivo cell therapy & antibody-drug conjugate candidates * BNTX has agreed to purchase $200 million of Autolus’ ADS in a private placement. BNTX will have a right to appoint director to AUTL Board. * BNTX to make a cash payment of $50 mil for BNTX to receive an up to mid-single digit royalty on obe-cel net sales.
1 · Reply
Chau_Mau
Chau_Mau Feb. 13 at 7:57 PM
The crux of the ongoing litigation between $ABUS and $MRNA, $PFE and $BNTX is this. Like the dog without its fur out in the cold that won't survive, the naked mRNA will not either in the hostile environment of the human body. It needs that coat of fur which we call the LNP technology that has been developed by Arbutus. Quite simple really! And yet, here we are, counting how many golden hair and brown hair the dog has before ascribing credit when it is a fact that without this enabling technology, the vaccine would have never come together in the first place.
1 · Reply
Quantumup
Quantumup Feb. 13 at 3:32 PM
Craig-Hallum🏁 $CMPX ~argues Tovecimig already met the ORR 1° of a Ph3 2L BTC study/ PFS/OS data is expected in Mar—expects these data to support a pot '27 comm launch in 2L BTC (models a $1B peak oppy)—+sees sig⬆️pot from early-stage pipeline. $AZN $ BMY $BNTX $DCTH MRK Here's what else Craig-Hallum said in its initiation report: https://x.com/Quantumup1/status/2022332075974488090?s=20
0 · Reply
taxplanr
taxplanr Feb. 13 at 2:54 PM
Just think how many failed startups wish they had investors as dumb as $BNTX bulls Are insiders bhedging with $IBRX or hedging inflation with $SLV and $GLD https://finviz.com/quote.ashx?t=BNTX&p=d
0 · Reply
taxplanr
taxplanr Feb. 13 at 1:44 AM
$BNTX every February insiders dump stock after retail gets pumped
0 · Reply
DocPharm
DocPharm Feb. 12 at 10:10 PM
$ABUS re-read some old articles today Alexis Carpenter (Vancouver - ex-Genevant) Recognized by $BNTX
1 · Reply
taxplanr
taxplanr Feb. 12 at 1:32 AM
Another tumore erased with Ivermectin and Mebendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-b78?utm_source=post-email-title&publication_id=1385328&post_id=187689587&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 11 at 8:46 PM
National Cancer Institute getting in on the Ivermectin study $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/breaking-news-national-cancer-institute?utm_source=post-email-title&publication_id=1385328&post_id=187660926&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 11 at 2:36 PM
$MRNA $BNTX $MRK $BMY think a cancer vaccine will be easier to get approved https://www.thekingstonreport.com/p/fda-issues-moderna-a-75-refund-refuses?utm_source=post-email-title&publication_id=1103773&post_id=187576352&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Latest News on BNTX
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 16 days ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 10:45 PM EST - 4 weeks ago

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 4 weeks ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 5 weeks ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 2 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 9, 2025, 5:54 PM EST - 2 months ago

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 2 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 2 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 2 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 2 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 2 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 2 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 17, 2025, 6:17 PM EST - 3 months ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 3 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 3 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 3 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 3 months ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 3 months ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 3 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 3 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 3 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 3 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 3 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 4 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 4 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 4 months ago

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 5 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 5 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 5 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 5 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 5 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 5 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 5 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 5 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 5 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 6 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 6 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 6 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 5, 2025, 1:36 PM EDT - 6 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 1:56 PM EDT - 6 months ago

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 10:32 AM EDT - 6 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 6 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:52 AM EDT - 6 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 6:45 AM EDT - 6 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

Aug 1, 2025, 4:51 PM EDT - 7 months ago

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

MRNA PFE

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 7 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 7 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Aug 1, 2025, 5:59 AM EDT - 7 months ago

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

MRNA PFE

Pandemic darlings Moderna, BioNTech are now on two different paths

Jul 31, 2025, 7:00 AM EDT - 7 months ago

Pandemic darlings Moderna, BioNTech are now on two different paths

MRNA

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 7 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

WatchTheseTickers
WatchTheseTickers Feb. 13 at 9:31 PM
OLB sitting in that reversal pocket exhaustion, zero borrow supply, undervalued zone near .30 and can see $1.00+. Low float runners often ignite from setups exactly like this. Do your DD. $MRNA $BNTX $NVAX $PFE $LLY
0 · Reply
QHD
QHD Feb. 13 at 8:35 PM
$AUTL Key Points of this Agreement: Strategic alliance leverages manufacturing/commercial infrastructure as well as technology w/ aim to advance both companies’ auto CAR-T programs to market * $BNTX secures right to use AUTL’s manufacturing capacity in a cost-efficient set-up to accelerate development of BNT211 into pivotal trials in CLDN6+ tumors * BNTX to support launch & expansion of development program of AUTL’s lead cell therapy candidate obe-cel & will receive a royalty on net sales * BNTX has co-commercialization options for AUTO1/22 & AUTO6NG programs * BNTX has option to access suite of AUTL target binders & cell programming technologies to support BNTX’s development of in vivo cell therapy & antibody-drug conjugate candidates * BNTX has agreed to purchase $200 million of Autolus’ ADS in a private placement. BNTX will have a right to appoint director to AUTL Board. * BNTX to make a cash payment of $50 mil for BNTX to receive an up to mid-single digit royalty on obe-cel net sales.
1 · Reply
Chau_Mau
Chau_Mau Feb. 13 at 7:57 PM
The crux of the ongoing litigation between $ABUS and $MRNA, $PFE and $BNTX is this. Like the dog without its fur out in the cold that won't survive, the naked mRNA will not either in the hostile environment of the human body. It needs that coat of fur which we call the LNP technology that has been developed by Arbutus. Quite simple really! And yet, here we are, counting how many golden hair and brown hair the dog has before ascribing credit when it is a fact that without this enabling technology, the vaccine would have never come together in the first place.
1 · Reply
Quantumup
Quantumup Feb. 13 at 3:32 PM
Craig-Hallum🏁 $CMPX ~argues Tovecimig already met the ORR 1° of a Ph3 2L BTC study/ PFS/OS data is expected in Mar—expects these data to support a pot '27 comm launch in 2L BTC (models a $1B peak oppy)—+sees sig⬆️pot from early-stage pipeline. $AZN $ BMY $BNTX $DCTH MRK Here's what else Craig-Hallum said in its initiation report: https://x.com/Quantumup1/status/2022332075974488090?s=20
0 · Reply
taxplanr
taxplanr Feb. 13 at 2:54 PM
Just think how many failed startups wish they had investors as dumb as $BNTX bulls Are insiders bhedging with $IBRX or hedging inflation with $SLV and $GLD https://finviz.com/quote.ashx?t=BNTX&p=d
0 · Reply
taxplanr
taxplanr Feb. 13 at 1:44 AM
$BNTX every February insiders dump stock after retail gets pumped
0 · Reply
DocPharm
DocPharm Feb. 12 at 10:10 PM
$ABUS re-read some old articles today Alexis Carpenter (Vancouver - ex-Genevant) Recognized by $BNTX
1 · Reply
taxplanr
taxplanr Feb. 12 at 1:32 AM
Another tumore erased with Ivermectin and Mebendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-b78?utm_source=post-email-title&publication_id=1385328&post_id=187689587&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 11 at 8:46 PM
National Cancer Institute getting in on the Ivermectin study $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/breaking-news-national-cancer-institute?utm_source=post-email-title&publication_id=1385328&post_id=187660926&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 11 at 2:36 PM
$MRNA $BNTX $MRK $BMY think a cancer vaccine will be easier to get approved https://www.thekingstonreport.com/p/fda-issues-moderna-a-75-refund-refuses?utm_source=post-email-title&publication_id=1103773&post_id=187576352&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Sabini
Sabini Feb. 11 at 12:42 PM
Does FDA decision on $MRNA flu vaccine have any impact on $BNTX mRNA plattform for cancer or other indications? Looks to me like there might be some collateral damage .
0 · Reply
taxplanr
taxplanr Feb. 11 at 3:12 AM
What are the chances he didn't have the chicken pox vaccine also? $BNTX $MRNA $PFE https://trendingpoliticsnews.com/star-actor-dies-suddenly-at-33-jrupp/?utm_source=DS21
0 · Reply
taxplanr
taxplanr Feb. 11 at 2:57 AM
$IBRX now approved in Saudi Arabia for lung breast pancreatic and brain cancer Why aren't they interested in malignantRNA from $BNTX $MRNA? $BMY $MRK https://www.instagram.com/reel/DUWf9oVkmB1/?igsh=MW85eXFlNnh2d2UybQ==
1 · Reply
taxplanr
taxplanr Feb. 10 at 8:44 PM
4 month Cancer turn around with Ivermectin and Fenbendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-446?utm_source=post-email-title&publication_id=1385328&post_id=187543408&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
1 · Reply
taxplanr
taxplanr Feb. 10 at 2:41 PM
Huge Tumor Decrease with CBD oil Ivermectin and Mebendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-mebendazole-and-fenbendazole-c0a?utm_source=post-email-title&publication_id=1385328&post_id=187453624&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 10 at 2:39 PM
Cancer Free in 6 months with Ivermectin and Fendendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-mebendazole-and-fenbendazole-c0a?utm_source=post-email-title&publication_id=1385328&post_id=187453624&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 10 at 1:43 PM
$IBRX is the Cancer Cure story while ineffective lipids from $MRNA $BNTX $BMY $MRK struggle through trials with lackluster results https://finviz.com/news/305407/immunitybio-ibrx-jumps-ahead-of-oncology-event
0 · Reply
Estimize
Estimize Feb. 10 at 11:00 AM
Wall St is expecting -2.33 EPS for $BNTX Q1 [Reporting 05/11 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_c
0 · Reply
DocPharm
DocPharm Feb. 10 at 2:54 AM
$ABUS the misinformation on reddit is crazy People please understand: $MRNA couldn’t just solve the issue by buying ABUS, because Genevant, a private company owned by $ROIV and ABUS, is the sole licensor. This dates WAY back to 2016 when a Canadian judge told MRNA to pound the metaphorical sand, for all but 4 indications. This was the same trial that gave $ALNY its rights to the same LNP for ONPATTRO. This was the same LNP that $BNTX licensed, outside of Covid (so far). ….Any redditors who would like to steal this and post it up, be my guest. You can even take full credit.
1 · Reply
taxplanr
taxplanr Feb. 10 at 1:42 AM
Embolism from rectal cancer $BNTX $MRNA $PFE https://trendingpoliticsnews.com/iconic-star-catherine-oharas-cause-of-death-officially-revealed-mace/?utm_source=DS21
0 · Reply
taxplanr
taxplanr Feb. 10 at 12:52 AM
Ivermectin Mebendazole and Fenbendazole taking care of triple negative Breast Cancer $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-mebendazole-and-fenbendazole-c0a?utm_source=post-email-title&publication_id=1385328&post_id=187453624&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Feb. 9 at 8:49 PM
$LLY buying Orna Therapeutics "Experiments to date suggest that Orna's circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms." $BNTX $MRNA $BMY $MRK being left behind https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies
0 · Reply